Serum ACSL4 levels in prostate cancer patients and its relationship between patient prognosis: A prospective observational study

Hao Wang,Hanfeng Xu,Yuan Yang
DOI: https://doi.org/10.1097/md.0000000000039119
IF: 1.6
2024-10-09
Medicine
Abstract:According to Global Cancer Statistics 2020, prostate cancer (PCa) is the most commonly diagnosed male cancer in 112 countries, and it ranks second in terms of mortality among all types of cancer in male cancer patients, second only to lung cancer. [ 1 , 2 ] Due to population growth and aging, it is projected that by 2040, global PCa will increase to nearly 2.3 million new cases and 740,000 deaths. [ 3 ] Early-stage PCa often presents no apparent symptoms, while late-stage PCa has poor overall treatment efficacy and high mortality rates. Despite the emergence of various new technologies and endocrine therapies for late-stage PCa, the mortality rate of PCa continues to rise. [ 4 ] Therefore, although prostate-specific antigen (PSA) levels have been widely used in the diagnosis of PCa, [ 5 , 6 ] there is still a need to identify new serum markers for early detection of PCa, which would significantly improve patient treatment and prognosis.
medicine, general & internal
What problem does this paper attempt to address?